BMS-214662 (Bristol-Myers Squibb).
Bristol-Myers Squibb is developing BMS-214662, a farnesyl transferase inhibitor, for the potential treatment of cancer. By October 2000, preclinical investigations were ongoing in Japan. By February 2001, the drug was in phase II trials in the US for pancreatic, head and neck, lung and colorectal cancers.
Johnston
Stephen R D
SR
Department of Medicine (Breast Unit), Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK. stephen@icr.ac.uk
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors*; D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D051231:Farnesyltranstransferase; D006801:Humans; D007093:Imidazoles / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D007093:Imidazoles; D001569:Benzodiazepines; D019883:Alkyl and Aryl Transferases; D051231:Farnesyltranstransferase; C415151:7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine